1
|
A review of nasal, paranasal, and skull base tumors invading the orbit. Surv Ophthalmol 2017; 63:389-405. [PMID: 28739401 DOI: 10.1016/j.survophthal.2017.07.001] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/20/2017] [Revised: 07/16/2017] [Accepted: 07/17/2017] [Indexed: 11/20/2022]
Abstract
Tumors that invade the orbit are uncommon. The majority are meningiomas arising from the sphenoid ridge (66%). Others are bone and cartilage tumors arising from the surrounding bones of the orbit, pituitary adenomas, and epithelial tumors arising from the paranasal sinuses and nasal cavity. Meningiomas occur more often in women, whereas epithelial tumors have a predilection for men. Meningiomas and epithelial tumors typically present in the sixth decade of life, whereas bone tumors tend to affect individuals in their third decade of life. Patients often present with a combination of ophthalmological and otorhinolaryngological symptoms, including proptosis, pain, decreased visual acuity, restrictions in motility of the eye, epistaxis, and nasal obstruction. Sarcomas and benign bone and cartilage tumors arise from surrounding structures, whereas carcinomas usually arise from the paranasal sinuses. Surgery is the mainstay of treatment. Depending on the aggressiveness and histology of the tumor, surgery may be combined with radiation and chemotherapy. The prognosis is generally poor, but varies depending on histology and cell origin, size of the tumor, and degree of invasion. Meningiomas and benign bone tumors have the best prognoses. Sinonasal undifferentiated carcinomas, small-cell neuroendocrine carcinomas, osteosarcomas, and rhabdomyosarcomas have poorer prognoses.
Collapse
|
2
|
Naguib MM, Mendoza PR, Jariyakosol S, Grossniklaus HE. Atypical pituitary adenoma with orbital invasion: Case report and review of the literature. Surv Ophthalmol 2017; 62:867-874. [PMID: 28131872 DOI: 10.1016/j.survophthal.2017.01.005] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2016] [Revised: 01/16/2017] [Accepted: 01/17/2017] [Indexed: 11/26/2022]
Abstract
Pituitary adenoma invasion into the orbit is a rare phenomenon with only 22 cases, including the present case, in the literature. Our case is a 31-year-old man who presented with biopsy-proven atypical pituitary adenoma invading the right orbit after a prior resection. We compare his clinical course with previous cases and discuss clinical features, radiological features, management considerations, histologic features, and prognosis. Cases are organized by specific pituitary tumor type to aid in determining appropriate management. Early surgical intervention is the key, especially in the setting of pathologic features indicating aggressive tumor behavior or worsening visual function but is generally not indicated in prolactin-secreting adenomas that may respond to medical therapy. The role of radiation therapy is not fully established; however, it should be strongly considered in conjunction with or after surgery, especially in cases where complete resection is not achieved or histological and molecular analyses indicate a high likelihood of recurrence. More uniform and comprehensive data about management and outcomes are needed to determine the optimal treatment approach for this rare entity.
Collapse
Affiliation(s)
- Mina M Naguib
- Department of Ophthalmology, Emory University School of Medicine, Atlanta, Georgia, USA
| | - Pia R Mendoza
- Department of Ophthalmology, Emory University School of Medicine, Atlanta, Georgia, USA; Department of Pathology, Emory University School of Medicine, Atlanta, Georgia, USA
| | - Supharat Jariyakosol
- Department of Ophthalmology, Chulalongkorn University, Bangkok, Thailand; King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand
| | - Hans E Grossniklaus
- Department of Ophthalmology, Emory University School of Medicine, Atlanta, Georgia, USA; Department of Pathology, Emory University School of Medicine, Atlanta, Georgia, USA.
| |
Collapse
|
3
|
Abstract
Giant prolactinomas are rare tumours, representing only 2-3% of all prolactin (PRL)-secreting tumours and raising special diagnostic and therapeutic challenges. Based on several considerations developed in this review, their definition should be restricted to pituitary adenomas with a diameter of 40 mm or more, significant extrasellar extension, very high PRL concentrations (usually above 1000 μg/l) and no concomitant GH or ACTH secretion. Giant prolactinomas are much more frequent in young to middle-aged men than in women, with a male to female ratio of about 9:1. Endocrine symptoms are often present but overlooked for a long period of time, and diagnosis is eventually made when neurologic complications arise from massive extension into the surrounding structures, leading to cranial nerve palsies, hydrocephalus, temporal epilepsy or exophthalmos. PRL concentrations are usually in the range of 1000-100,000 μg/l, but may be underestimated by the so-called 'high-dose hook effect'. As in every prolactinoma, dopamine agonists are the first-line treatment allowing rapid alleviation of neurologic symptoms in the majority of the cases, a significant reduction in tumour size in three-fourths of the patients and PRL normalization in 60-70%. These extensive tumours are usually not completely resectable and neurosurgery has significant morbidity and mortality. It should therefore be restricted to acute complications such as apoplexy or leakage of cerebrospinal fluid (often induced by medical treatment) or to patients with insufficient tumoural response or progression. Irradiation and temozolomide are useful adjuvant therapies in a subset of patients with aggressive/invasive tumours, which are not controlled despite combined medical and surgical treatments. Because of these various challenges, we advocate a multidisciplinary management of these giant tumours in expert centres.
Collapse
Affiliation(s)
- Dominique Maiter
- Department of EndocrinologyCliniques Universitaires Saint-LucCentre Hospitalier Universitaire de Mont-GodinneMont-sur-Meuse, Université catholique de Louvain, Avenue Hippocrate 54.74, 1200 Brussels, Belgium
| | - Etienne Delgrange
- Department of EndocrinologyCliniques Universitaires Saint-LucCentre Hospitalier Universitaire de Mont-GodinneMont-sur-Meuse, Université catholique de Louvain, Avenue Hippocrate 54.74, 1200 Brussels, Belgium
| |
Collapse
|
4
|
Cackett P, Eunson G, Bath L, Mulvihill A. Proptosis as the presenting sign of giant prolactinoma in a prepubertal boy: successful resolution of hydrocephalus by use of medical therapy. Future Oncol 2013; 8:1621-6. [PMID: 23231524 DOI: 10.2217/fon.12.149] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
We report the case of a 13-year-old prepubertal boy who presented with a left-sided proptosis, bilateral papilloedema and hydrocephalus who was subsequently diagnosed with a giant prolactinoma invading the left orbit. He was commenced on dopamine receptor agonists in the form of quinagolide and cabergoline, and made an excellent response to medical therapy alone, with resolution of hydrocephalus, restoration of normal vision and a 98% reduction in serum prolactin. The rapid improvement achieved negated the requirement for surgery and this highlights the efficacy of the dopamine agonists in the management of giant prolactinomas, even in the presence of neurological symptoms.
Collapse
Affiliation(s)
- Peter Cackett
- Department of Ophthalmology, Princess Alexandra Eye Pavilion, Chalmers Street, Edinburgh, EH3 9HA, UK.
| | | | | | | |
Collapse
|
5
|
SIDDIQUI A, CHEW N, MISZKIEL K. Unusual orbital invasion by a giant prolactinoma. Br J Radiol 2008; 81:e259-62. [DOI: 10.1259/bjr/98771490] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
|
6
|
Semple P, Fieggen G, Parkes J, Levitt N. Giant prolactinomas in adolescence: an uncommon cause of blindness. Childs Nerv Syst 2007; 23:213-7. [PMID: 16983572 DOI: 10.1007/s00381-006-0177-5] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/10/2005] [Revised: 01/10/2006] [Indexed: 11/24/2022]
Abstract
INTRODUCTION Prolactinomas in childhood and adolescence are rare. However, in male patients in particular they may become extremely large and invasive, resulting in visual impairment without necessarily producing endocrine symptoms. CASE REPORTS We report on two adolescent males who presented with deteriorating vision over a long period of time and who had optic atrophy on examination. Magnetic resonance imaging identified tumours with extensive anterior skull base invasion and suprasellar extension. Prolactin levels in both patients were markedly elevated, and a diagnosis of prolactinoma was made. Bromocriptine treatment was started resulting in lowered prolactin levels, improved vision and tumour shrinkage on imaging. CONCLUSION A male child or adolescent presenting with diminished vision and found to have suprasellar or anterior skull base tumour should have their prolactin levels checked to rule out a prolactinoma, which can be successfully managed with medical therapy.
Collapse
Affiliation(s)
- Patrick Semple
- OH 53 OMB, Groote Schuur Hospital, Observatory 7925, Cape Town, South Africa.
| | | | | | | |
Collapse
|
7
|
Vaudaux J, Portmann L, Maeder P, Borruat FX. Orbital invasion by a pituitary macroadenoma without visual loss: case report and review of the literature. Eye (Lond) 2004; 17:1032-4. [PMID: 14704754 DOI: 10.1038/sj.eye.6700481] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022] Open
|
8
|
Bernardini FP, Kersten RC, Moin M, Kulwin DR. Unsuspected recurrent pituitary adenoma presenting as an orbital mass. Ophthalmic Plast Reconstr Surg 2001; 17:140-3. [PMID: 11281590 DOI: 10.1097/00002341-200103000-00014] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
PURPOSE Orbital invasion of pituitary tumors is rare and usually accompanied by optic nerve head pallor and visual loss. We describe a case of unilateral massive orbital invasion by a recurrent pituitary tumor with preserved visual acuity and normal optic nerve appearance. METHODS Case report. RESULTS Progressive proptosis developed 15 years after transphenoidal removal of a pituitary tumor. Based on the radiological appearance and the clinical history, the patient was suspected to have a sphenoid wing meningioma secondary to previous radiation treatment. A combined neurosurgical and orbital approach was used to remove the intraorbital mass, which extended from the cranial cavity through the superior orbital fissure and the optic canal. Histopathologic examination demonstrated a recurrent nonsecreting pituitary adenoma. CONCLUSIONS Orbital extension of a recurrent pituitary adenoma should be considered in the differential diagnosis of progressive proptosis even in the absence of significant optic neuropathy.
Collapse
Affiliation(s)
- F P Bernardini
- Department of Ophthalmology, University of Cincinnati College of Medicine, Ohio, USA
| | | | | | | |
Collapse
|
9
|
Berwaerts J, Verhelst J, Abs R, Appel B, Mahler C. A giant prolactinoma presenting with unilateral exophthalmos: effect of cabergoline and review of the literature. J Endocrinol Invest 2000; 23:393-8. [PMID: 10908167 DOI: 10.1007/bf03343743] [Citation(s) in RCA: 20] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
We report the case of a 45-year-old male presenting with unilateral exophthalmos due to a large tumoral mass invading the skull base. Ophthalmologic examination did not show any visual field defects. Imaging techniques demonstrated extension of a huge tumor (approx. 8x8x8 cm) into the right orbit and nasopharynx. Endocrine work-up revealed grossly elevated serum prolactin (PRL) levels (26,466 microg/l, nl. < 12), pointing to a large, invasive macroprolactinoma. Stimulation tests indicated associated partial adrenal and growth hormone deficiencies. Planned surgery was abandoned, and the patient was instead treated with the long-acting dopamine agonist, cabergoline. Over a period of one year, serum PRL dropped to 131 microg/l, while the tumor mass shrank to less than 50% of its original volume (with 3.5 mg/week of cabergoline). The exophthalmos disappeared, and the patient did not develop rhinorrhea or any other side effects from treatment with cabergoline. The efficacy was maintained throughout the second year (ultimate serum PRL 74 microg/l, and final size less than 10% of the original). With reference to this case, we review other macroprolactinomas reported in the recent literature for associated exophthalmos, grossly elevated serum PRL levels (> or = 15,000 microg/l), and/or "giant" size (> or = 4 cm in maximum diameter). We highlight the use of dopamine agonists in the treatment of prolactinomas with such unusual characteristics.
Collapse
Affiliation(s)
- J Berwaerts
- Department of Endocrinology, Middelheim Hospital, Antwerp, Belgium. Joris_M_Berwaerts@SB_PHARM_RD
| | | | | | | | | |
Collapse
|
10
|
Cesario F, Borretta G, Meineri I, Muratori M, Pizzocaro A, Beck-Peccoz P. Combined cabergoline and recombinant human growth hormone treatment of an adolescent with a macroprolactinoma causing GH deficiency. J Pediatr Endocrinol Metab 1997; 10:231-6. [PMID: 9364359 DOI: 10.1515/jpem.1997.10.2.231] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
The rare macroprolactinomas seen in childhood frequently cause delayed puberty and GH deficiency. We report the combined use of cabergoline and recombinant human GH (rhGH) therapy in a male adolescent with macroprolactinoma and GH deficiency. Computed tomography and magnetic resonance imaging of the hypothalamic-pituitary region showed a macroadenoma with extrasellar extension. Neither bromocriptine nor dihydroergocryptine therapy was successful in decreasing serum PRL levels. On cabergoline treatment normal serum PRL levels were achieved within 3 months along with a marked shrinkage of the adenoma but growth rate did not increase nor did puberty start. The addition of exogenous rhGH therapy improved the growth rate, but complete pubertal development was obtained only after the administration of exogenous gonadotropins. During the combined treatment no expansion of the macroadenoma was observed. In conclusion, the combined therapy with cabergoline and rhGH seems to be safe and highly effective. Nevertheless, it warrants careful monitoring and on-going evaluation.
Collapse
Affiliation(s)
- F Cesario
- Divisione di Endocrinologia Ospedale S. Croce, Cuneo, Italy
| | | | | | | | | | | |
Collapse
|
11
|
Abstract
Prolactin secreting pituitary adenomas are a rare finding in prepubertal children /1/. As in adults, their incidence is higher in girls than in boys; however, the macroadenomas are predominant in boys /20-16/. Two prepubertal boys who presented with short stature and linear growth deceleration were diagnosed to have prolactin secreting pituitary macroadenoma associated with growth hormone (GH) deficiency. They were treated with bromocryptine and exogenous recombinant hGH. They achieved a normal adult stature, full sexual maturation and tumor regression on the therapy. In addition, both boys developed macrotestes. Further evaluation ruled out other etiologies for macrotestes. We presume that the elevated prolactin caused local testicular growth factors to induce testicular cell division and/or hypertrophy resulting in an increased testicular volume.
Collapse
Affiliation(s)
- R H Ruvalcaba
- Department of Pediatrics, University of Washington, Tacoma, USA
| | | | | |
Collapse
|
12
|
Nischal KK, James N, Kanski JJ. Proptosis precipitated by retinal detachment repair in a patient with occult pituitary tumour. Eye (Lond) 1995; 9 ( Pt 5):647-9. [PMID: 8543091 DOI: 10.1038/eye.1995.158] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023] Open
|
13
|
Oliveira MDC, Abech DD, Barbosa-Coutinho LM, Ferreira NP. [Macroprolactinoma at 6 years of age: diagnostic difficulties]. ARQUIVOS DE NEURO-PSIQUIATRIA 1992; 50:397-401. [PMID: 1308423 DOI: 10.1590/s0004-282x1992000300024] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
Prolactinoma is rare in childhood and adolescence. The earliest known diagnosis was reported in a patient at 8 years of age. We report the case of a sellar tumor found in a 6 years old girl. After a long symptomatic period she was brought for treatment. At this time she had partial papillar atrophy, hyperprolactinemia, and diminished reserve of growth hormone and cortisol. Due to rapid visual deterioration, she was submitted to a frontotemporal craniotomy for suspected craniopharyngioma. The tumor tissue immunohistochemistry was positive for prolactin. It is concluded that prolactinoma must be considered in differential diagnosis of sellar tumors in childhood since it benefits from a less aggressive therapy.
Collapse
Affiliation(s)
- M da C Oliveira
- Disciplina de Endocrinologia da Fundação Faculdade Federal de Ciências Médicas de Porto Alegre (FFFCLMPA), Brasil
| | | | | | | |
Collapse
|